Equities

Brainsway Ltd

Brainsway Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)8.21
  • Today's Change-0.05 / -0.61%
  • Shares traded46.56k
  • 1 Year change+109.44%
  • Beta1.2540
Data delayed at least 15 minutes, as of Sep 26 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

  • Revenue in USD (TTM)63.57m
  • Net income in USD-8.39m
  • Incorporated2006
  • Employees134.00
  • Location
    Brainsway Ltd19 Hartum StBynet Building, Har HotzvimJERUSALEM 9777518IsraelISR
  • Phone+972 25824030
  • Fax+972 25812517
  • Websitehttps://www.brainsway.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Edap Tms SA (ADR)69.07m-21.89m107.88m307.00--2.03--1.56-0.5904-0.59041.861.430.69922.373.42224,993.60-22.16-6.62-31.50-9.2240.3443.23-31.69-9.591.80--0.0599--9.649.05-622.06--32.75--
Myomo Inc21.11m-9.45m115.46m101.00--11.92--5.47-0.2614-0.26140.58330.32041.433.5010.13209,020.40-64.07-81.78-101.11-115.2767.3568.50-44.75-85.761.94--0.00--23.7051.0924.00--2.82--
Harvard Bioscience, Inc.101.13m-10.68m116.01m391.00--1.73--1.15-0.2471-0.24712.351.540.74411.646.88258,631.70-7.86-3.29-9.44-3.8958.3956.67-10.56-4.570.9416-1.310.3467---0.9573-1.4564.11--18.10--
Fonar Corp102.72m10.29m117.71m561.0011.840.71026.241.151.481.4814.7224.700.502319.991.41183,098.207.168.737.409.6045.5548.3314.2616.399.16--0.0051--1.083.89-24.71-15.058.48--
908 Devices Inc.52.69m-37.99m119.57m230.00--0.7641--2.27-1.15-1.151.604.520.25111.544.95229,069.60-18.11-14.16-20.12-15.3552.3253.02-72.10-64.254.23--0.00--7.2117.89-8.45--22.98--
KORU Medical Systems Inc30.82m-11.76m123.81m82.00--6.61--4.02-0.2574-0.25740.67420.40820.97372.946.50375,817.30-37.15-17.60-43.48-20.2962.4959.44-38.16-21.703.27--0.0195--2.2310.44-58.65--11.10--
InfuSystem Holdings Inc129.37m366.00k127.04m499.00380.592.3810.140.9820.01570.01575.992.511.2210.386.44259,264.500.34654.600.4015.6949.6856.430.28294.071.641.970.38980.0014.4413.384,744.44--6.01--
Akoya Biosciences Inc93.22m-60.35m134.64m330.00--6.05--1.44-1.22-1.221.890.44980.56051.936.34282,472.70-36.29---45.98--57.57---64.74--1.98-8.000.7755--29.09--10.36------
EUDA Health Holdings Ltd3.71m-8.44m134.89m106.00------36.39-0.3685-0.43840.1707-0.30450.2752--3.5534,966.61-62.62------22.72---227.57-----1.49-----1.54--66.17------
Brainsway Ltd - ADR63.57m-8.39m138.87m134.00------2.18-0.5071-0.50713.86--0.49882.207.37---6.59---8.54--73.86---13.20--5.49------16.96--68.56------
Acme United Corp192.71m19.45m155.08m645.008.441.496.200.80474.974.9748.5928.131.152.074.83298,770.5011.607.0913.798.2939.4035.7210.095.501.776.600.262118.81-1.276.88486.3131.089.024.84
Semler Scientific Inc61.74m15.82m158.52m92.0011.152.029.622.572.032.037.9311.220.770616.269.15671,097.8019.7438.8322.0044.4188.6790.2225.6232.583.66--0.00--20.2825.9843.6932.64-0.3821--
Stereotaxis Inc23.75m-22.08m168.47m122.00--14.54--7.09-0.265-0.2650.2850.2020.56321.145.04194,639.30-49.21-25.02-71.93-34.1259.2867.57-87.38-41.901.53--0.00---4.89-1.82-12.33--6.63--
Electromed Inc54.72m5.15m169.75m174.0033.933.8128.333.100.57910.57916.175.161.123.272.25314,459.8010.518.6412.5110.0976.2676.269.418.065.27--0.000.0013.8311.8262.6721.06-22.23--
Accuray Inc446.55m-15.55m170.46m987.00--3.78--0.3817-0.1591-0.15914.540.450.94232.145.36452,432.60-3.28-1.37-5.61-2.3332.0536.43-3.48-1.550.9470.26230.7925---0.23551.29-67.51---3.54--
Orchestra Biomed Holdings Inc2.08m-55.58m177.40m56.00--3.81--85.33-1.57-1.570.05861.230.0211.3416.5737,125.00-56.06---64.66--92.02---2,673.26--4.58--0.00---21.88---37.91------
Data as of Sep 26 2024. Currency figures normalised to Brainsway Ltd's reporting currency: US Dollar USD

Institutional shareholders

19.82%Per cent of shares held by top holders
HolderShares% Held
Masters Capital Management LLCas of 30 Jun 2024900.00k5.40%
Phoenix Investments House Ltd.as of 30 Jun 2024804.98k4.83%
Essex Investment Management Co. LLCas of 30 Jun 2024346.87k2.08%
DAFNA Capital Management LLCas of 30 Jun 2024297.66k1.79%
Renaissance Technologies LLCas of 30 Jun 2024277.10k1.66%
Acadian Asset Management LLCas of 30 Jun 2024259.79k1.56%
Cresset Asset Management LLCas of 30 Jun 2024157.46k0.94%
Legato Capital Management LLCas of 30 Jun 2024117.21k0.70%
Marshall Wace LLPas of 30 Jun 202484.93k0.51%
Walleye Capital LLCas of 30 Jun 202459.00k0.35%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.